- Home
- SLND vs VYGR Comparison
SLND vs VYGR Comparison
Compare SLND & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLND
- VYGR
- Stock Information
- Founded
- SLND 1900
- VYGR 2013
- Country
- SLND United States
- VYGR United States
- Employees
- SLND N/A
- VYGR N/A
- Industry
- SLND Military/Government/Technical
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- SLND Industrials
- VYGR Health Care
- Exchange
- SLND Nasdaq
- VYGR Nasdaq
- Market Cap
- SLND 175.8M
- VYGR 156.0M
- IPO Year
- SLND N/A
- VYGR 2015
- Fundamental
- Price
- SLND $3.84
- VYGR $3.30
- Analyst Decision
- SLND Strong Buy
- VYGR Strong Buy
- Analyst Count
- SLND 1
- VYGR 8
- Target Price
- SLND $5.00
- VYGR $14.33
- AVG Volume (30 Days)
- SLND 47.3K
- VYGR 665.3K
- Earning Date
- SLND 05-13-2025
- VYGR 05-06-2025
- Dividend Yield
- SLND N/A
- VYGR N/A
- EPS Growth
- SLND N/A
- VYGR N/A
- EPS
- SLND N/A
- VYGR N/A
- Revenue
- SLND $931,568,000.00
- VYGR $66,958,000.00
- Revenue This Year
- SLND $3.76
- VYGR N/A
- Revenue Next Year
- SLND $1.08
- VYGR $45.34
- P/E Ratio
- SLND N/A
- VYGR N/A
- Revenue Growth
- SLND N/A
- VYGR N/A
- 52 Week Low
- SLND $1.85
- VYGR $2.65
- 52 Week High
- SLND $5.76
- VYGR $9.55
- Technical
- Relative Strength Index (RSI)
- SLND 65.06
- VYGR 53.05
- Support Level
- SLND $3.77
- VYGR $2.65
- Resistance Level
- SLND $4.00
- VYGR $3.51
- Average True Range (ATR)
- SLND 0.15
- VYGR 0.21
- MACD
- SLND -0.01
- VYGR 0.04
- Stochastic Oscillator
- SLND 51.35
- VYGR 60.19
About SLND Southland Holdings Inc.
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.